Partial suppression of M1 microglia by Janus kinase 2 inhibitor does not protect against neurodegeneration in animal models of amyotrophic lateral sclerosis

Journal of Neuroinflammation

Volumn 11, Issue 1, 2014, Pages

  Tada, Satoru ^a,b   Okuno, Tatsusada ^a   Hitoshi, Yasumichi ^c   Yasui, Teruhito ^b   Honorat, Josephe Archie ^a   Takata, Kazushiro ^a   Koda, Toru ^a   Shimagami, Hiroshi ^a   Chi Jing, Choong ^a   Namba, Akiko ^a   Sugimoto, Tomoyuki ^d   Sakoda, Saburo ^e   Mochizuki, Hideki ^a   Kikutani, Hitoshi ^b   Nakatsuji, Yuji ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c RIGEL PHARMACEUTICALS INC   (United States)

^d HIROSAKI UNIVERSITY   (Japan)

^e TONEYAMA NATIONAL HOSPITAL   (Japan)

Author keywords

Amyotrophic lateral sclerosis; Interferon gamma; JAK2 inhibitor; Janus kinase 2; M1 M2 microglia; Neuroinflammation; R723; SOD1 G93A transgenic mice

Indexed keywords

BIOLOGICAL MARKER; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; R 723; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; RESISTIN LIKE ALPHA; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; ENZYME INHIBITOR; JAK2 PROTEIN, MOUSE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; MICROGLIA; MONOCYTE; MOUSE; MSOD1 MOUSE; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION; SPINAL CORD; SURVIVAL; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; ENZYMOLOGY; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; PATHOLOGY; TRANSGENIC MOUSE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; JANUS KINASE 2; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROGLIA; NERVE DEGENERATION; SPINAL CORD;

EID: 84965183656     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/s12974-014-0179-2     Document Type: Article

References (19)

1. Tada S, Okuno T, Yasui T, Nakatsuji Y, Sugimoto T, Kikutani H, Sakoda S: Deleterious effects of lymphocytes at the early stage of neurodegeneration in an animal model of amyotrophic lateral sclerosis. J Neuroinflammation 2011, 8:19.
2. Tada S, Yasui T, Nakatsuji Y, Okuno T, Koda T, Mochizuki H, Sakoda S, Kikutani H: BAFF controls neural cell survival through BAFF receptor. PLoS One 2013, 8:e70924.
3. Zhao W, Beers DR, Appel SH: Immune-mediated mechanisms in the pathoprogression of amyotrophic lateral sclerosis. J Neuroimmune Pharmacol 2013, 8:888-899.
4. Aebischer J, Cassina P, Otsmane B, Moumen A, Seilhean D, Meininger V, Barbeito L, Pettmann B, Raoul C: IFNgamma triggers a LIGHT-dependent selective death of motoneurons contributing to the non-cell-autonomous effects of mutant SOD1. Cell Death Differ 2011, 18:754-768.
5. Okuno T, Nakatsuji Y, Kumanogoh A, Koguchi K, Moriya M, Fujimura H, Kikutani H, Sakoda S: Induction of cyclooxygenase-2 in reactive glial cells by the CD40 pathway: relevance to amyotrophic lateral sclerosis. J Neurochem 2004, 91:404-412.
6. Butovsky O, Siddiqui S, Gabriely G, Lanser AJ, Dake B, Murugaiyan G, Doykan CE, Wu PM, Gali RR, Iyer LK, Lawson R, Berry J, Krichevsky AM, Cudkowicz ME, Weiner HL: Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS. J Clin Invest 2012, 122:3063-3087.
7. Vakil E, Tefferi A: BCR-ABL1-negative myeloproliferative neoplasms: a review of molecular biology, diagnosis, and treatment. Clin Lymphoma Myeloma Leuk 2011, 11(Suppl 1):S37-S45.
8. Kiu H, Nicholson SE: Biology and significance of the JAK/STAT signalling pathways. Growth Factors 2012, 30:88-106.
9. Seavey MM, Dobrzanski P: The many faces of Janus kinase. Biochem Pharmacol 2012, 83:1136-1145.
10. Liu Y, Holdbrooks AT, De Sarno P, Rowse AL, Yanagisawa LL, McFarland BC, Harrington LE, Raman C, Sabbaj S, Benveniste EN, Qin H: Therapeutic efficacy of suppressing the Jak/STAT pathway in multiple models of experimental autoimmune encephalomyelitis. J Immunol 2014, 192:59-72.
11. Stump KL, Lu LD, Dobrzanski P, Serdikoff C, Gingrich DE, Dugan BJ, Angeles TS, Albom MS, Ator MA, Dorsey BD, Ruggeri BA, Seavey MM: A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis. Arthritis Res Ther 2011, 13:R68.
12. Taylor P, Genovese M, Keystone E, Schlichting D, Beattie S, Macias W: A1.72 Baricitinib, an oral janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in an open-label, long-term extension study1. Ann Rheum Dis 2014, 73(1):A31.
13. Sandborn WJ, Ghosh S, Panes J, Vranic I, Wang W, Niezychowski W, Study AI: A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease. Clin Gastroenterol Hepatol 2014, 12:1485-1493.
14. Ports WC, Khan S, Lan S, Lamba M, Bolduc C, Bissonnette R, Papp K: A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Br J Dermatol 2013, 169:137-145.
15. Shide K, Kameda T, Markovtsov V, Shimoda HK, Tonkin E, Fang S, Liu C, Gelman M, Lang W, Romero J, McLaughlin J, Bhamidipati S, Clough J, Low C, Reitsma A, Siu S, Pine P, Park G, Torneros A, Duan M, Singh R, Payan DG, Matsunaga T, Hitoshi Y, Shimoda K: R723, a selective JAK2 inhibitor, effectively treats JAK2V617F-induced murine myeloproliferative neoplasm. Blood 2011, 117:6866-6875.
16. Beers DR, Zhao W, Liao B, Kano O, Wang J, Huang A, Appel SH, Henkel JS: Neuroinflammation modulates distinct regional and temporal clinical responses in ALS mice. Brain Behav Immun 2011, 25:1025-1035.
17. Reichel A: The role of blood-brain barrier studies in the pharmaceutical industry. Curr Drug Metab 2006, 7:183-203.
18. Bhattacharjee A, Shukla M, Yakubenko VP, Mulya A, Kundu S, Cathcart MK: IL-4 and IL-13 employ discrete signaling pathways for target gene expression in alternatively activated monocytes/macrophages. Free Radic Biol Med 2013, 54:1-16.
19. Zhao J, Li G, Zhang Y, Su X, Hang C: The potential role of JAK2/STAT3 pathway on the anti-apoptotic effect of recombinant human erythropoietin (rhEPO) after experimental traumatic brain injury of rats. Cytokine 2011, 56:343-350.